New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 2, 2012
16:15 EDTKERX, THRX, YPF, WG, GSK, GRPN, AVPOn The Fly: Closing Wrap
Stocks on Wall Street were higher after manufacturing reports in the U.S. and China indicated expansion. Stock futures traded below fair value for most of the pre-market trading session leading to a lower open for the broader market. The weakness was attributed to a high unemployment reading and a lackluster PMI report out of Europe. The market reversed its course and moved into positive territory following the slightly better than expected ISM manufacturing report here in the U.S. Once in positive territory the market moved quickly, but its advance stalled at a resistance level for the S&P. The move broadened out with the Nasdaq ending the day as the leading major index... ECONOMIC EVENTS: Domestically, the ISM manufacturing reading of 53.4 exceeded expectations for a 53.0 reading. Construction spending in February was down 1.1%, versus the expected increase of 0.6%. Internationally, an official reading of China's PMI rose to 53.1 while Markit's Eurozone manufacturing PMI fell to 47.7... MARKET NEWS: Avon Products (AVP) rejected the increased bid of $23.25 per share from fragrance-maker Coty. Avon shares rose $3.34, or 17.25%, to $22.70 following the announcement of the sweetened offer though Coty said it will not go hostile with its buyout plan... Groupon (GRPN) shares slid almost 17%, to $15.27, after the company announced weakness in its internal controls and revised its Q4 results lower... MAJOR MOVERS: Among the notable gainers were Willbros Group (WG), up 69c, or 21.30%, to $3.93, after its Q4 revenues beat expectations, and Theravance (THRX), up $3.79, or 19.44%, to $23.29, after GlaxoSmithKline (GSK) moved to raise its stake in the company to 26.8% with the purchase of 10M shares. Noteworthy losers included YPF SA (YPF), down $4.40, or 15.49%, to $24.01, following a downgrade at Merrill Lynch and a report that Argentina's government will take control of the company, and Keryx Biopharmaceuticals (KERX), down $3.24, or 65.06%, to $1.74, after the company announced that a trial for its lead drug missed its primary endpoint... INDICES: The Dow gained 52.45, or 0.40%, to 13,264.49; the Nasdaq added 28.13, or 0.91%, to 3,119.70; and the S&P 500 rose 10.43, or 0.74%, to 1,418.90.
News For AVP;GRPN;WG;THRX;GSK;YPF;KERX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 30, 2015
07:15 EDTAVPAvon Products reports Q2 adjusted EPS 11c, consensus 8c
Reports Q2 revenue $1.82B, consensus $1.80B.
July 29, 2015
16:50 EDTTHRXTheravance sees results from Salford COPD lung study in 2016
"Results from the SUMMIT chronic obstructive pulmonary disease study of 16,000 patients evaluating the impact of Relvar/Breo Ellipta on all-cause mortality among patients with COPD who have cardiovascular disease are expected to be available by year-end 2015. The Salford lung study in COPD is expected to complete by the end of 2015 with the first results expected in 2016," said the company.
16:48 EDTTHRXTheravance reports Q2 EPS (7c), consensus (6c)
Subscribe for More Information
14:49 EDTGSKGlaxoSmithKline probing new bribery allegations in Romania, Reuters reports
Subscribe for More Information
10:41 EDTKERXOptions with increasing implied volatility
Subscribe for More Information
10:27 EDTKERXOptions with decreasing implied volatility
Subscribe for More Information
08:00 EDTGSKGlaxoSmithKline reports Q2 global pharmaceuticals revenue GBP2.98B, down 12%
Reports Q2 HIV revenue GBP559M, up 59%. Reports Q2 Pharmaceuticals revenue GBP3.54B, down 6%, and vaccines revenue GBP814M, up 11%. Consumer healthcare sales were GBP1.51B, up 51% year over year.
07:58 EDTGSKGlaxoSmithKline sees FY16 core EPS to grow in double digits
Subscribe for More Information
07:57 EDTGSKGlaxoSmithKline reaffirms FY15 core EPS declining at high-teens percentage rate
Subscribe for More Information
07:54 EDTGSKGlaxoSmithKline reports Q2 adjusted EPS 17.3p, consensus 16.78p
Subscribe for More Information
July 27, 2015
17:31 EDTGSKRadius Health hires Dr. Lorraine Fitzpatrick as Chief Medical Officer
Radius Health (RDUS) announced that it has hired Dr. Lorraine A. Fitzpatrick as Chief Medical Officer of the Company. Dr. Fitzpatrick was previously Medicine Development Leader of an international clinical development team for Denosumab at GlaxoSmithKline (GSK), responsible for clinical development, regulatory, manufacturing, commercial, operations, epidemiology, and global health outcomes. Previously, Dr. Fitzpatrick led the clinical development of novel agents to treat musculoskeletal diseases and women's health at GlaxoSmithKline. Before joining GlaxoSmithKline, Dr. Fitzpatrick was Executive Director at Amgen, Inc. where she worked in the fields of osteoporosis and oncology.
08:26 EDTKERXKeryx appoints Scott Holmes as CFO
Keryx Biopharmaceuticals announced the appointment of Scott A. Holmes to CFO effective immediately. Holmes will be responsible for Keryx's finance function and will be a member of the company's executive team. He will succeed James Oliviero whose planned departure was announced earlier this year. Oliviero will stay with the company through a transition period. Holmes brings nearly 20 years of life sciences and financial management expertise to Keryx. He joins the company from AMAG Pharmaceuticals where he most recently served as senior vice president, finance and investor relations during a period of high growth driven by acquisitions and public financings. Prior to AMAG, from 2009 to 2011, he was vice president of finance and treasurer of Molecular Biometrics.
08:03 EDTGSKNephroGenex names Jaikrishna Patel as Chief Medical Officer
NephroGenex (NRX) announced the appointment of Dr. Jaikrishna Patel to the position of Chief Medical Officer. Dr. Patel will help guide the company’s Phase 3 PIONEER program with oral Pyridorin for the treatment of diabetic nephropathy, and the development of an intravenous formulation of Pyridorin for acute kidney injury. Patel has held numerous positions of increasing responsibility at GlaxoSmithKline (GSK) and its predecessor companies, most recently serving as Vice President of Cardiovascular and Cardiovascular Metabolism, Global Regulatory Affairs.
July 24, 2015
07:13 EDTKERXKeryx receives CHMP positive opinion for Fexeric
Subscribe for More Information
05:04 EDTGSKAgenus reports GSK Malaria vaccine receives positive opinion from CHMP of EMA
Subscribe for More Information
July 23, 2015
10:00 EDTKERXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:06 EDTKERXKeryx downgraded to Market Perform from Outperform at Cowen
Subscribe for More Information
July 21, 2015
10:01 EDTAVPOn The Fly: Analyst Initiation Summary
Subscribe for More Information
July 20, 2015
16:36 EDTAVPAvon Products initiated with a Neutral at Sterne Agee CRT
Subscribe for More Information
07:04 EDTWGWillbros Group wins new contracts that will generate C$120M-C$150M
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use